-
1
-
-
0037263849
-
Gastric cancer epidemiology and risk factors
-
DOI 10.1016/S0895-4356(02)00534-6, PII S0895435602005346
-
Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1-9 (Pubitemid 36183309)
-
(2003)
Journal of Clinical Epidemiology
, vol.56
, Issue.1
, pp. 1-9
-
-
Kelley, J.R.1
Duggan, J.M.2
-
3
-
-
33745547767
-
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
-
DOI 10.1200/JCO.2005.05.0245
-
Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909 (Pubitemid 46630593)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.18
, pp. 2903-2909
-
-
Wagner, A.D.1
Grothe, W.2
Haerting, J.3
Kleber, G.4
Grothey, A.5
Fleig, W.E.6
-
4
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712 (Pubitemid 19147683)
-
(1989)
Science
, vol.244
, Issue.4905
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
Holt, J.A.4
Wong, S.G.5
Keith, D.E.6
Levin, W.J.7
Stuart, S.G.8
Udove, J.9
Ullrich, A.10
Press, M.F.11
-
6
-
-
50849105191
-
Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit
-
Abstr 4053
-
Yano T, Ochiai A, Doi T et al (2004) Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol 22:14S(Abstr 4053)
-
(2004)
J Clin Oncol
, vol.22
-
-
Yano, T.1
Ochiai, A.2
Doi, T.3
-
7
-
-
33748154637
-
HER-2/neu amplification is an independent prognostic factor in gastric cancer
-
DOI 10.1007/s10620-005-9057-1
-
Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379 (Pubitemid 44315804)
-
(2006)
Digestive Diseases and Sciences
, vol.51
, Issue.8
, pp. 1371-1379
-
-
Park, D.I.1
Yun, J.W.2
Park, J.H.3
Oh, S.J.4
Kim, H.J.5
Cho, Y.K.6
Sohn, C.I.7
Jeon, W.K.8
Kim, B.I.9
Yoo, C.H.10
Son, B.H.11
Cho, E.Y.12
Chae, S.W.13
Kim, E.-J.14
Sohn, J.H.15
Ryu, S.H.16
Sepulveda, A.R.17
-
8
-
-
67650395450
-
Incidence of gastric or gastro-esophageal cancer in the ToGA trial: Correlation with HER2 positivity
-
abstr 11
-
Kang YK, Bang YJ, Lordick F et al (2008) Incidence of gastric or gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity. Gastrointestinal Cancers Symposium p. 75 (abstr 11)
-
(2008)
Gastrointestinal Cancers Symposium
, pp. 75
-
-
Kang, Y.K.1
Bang, Y.J.2
Lordick, F.3
-
9
-
-
0028907863
-
Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer
-
Tokunaga A, Onda M, Okuda T et al (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer. Cancer 75:1418-1425
-
(1995)
Cancer
, vol.75
, pp. 1418-1425
-
-
Tokunaga, A.1
Onda, M.2
Okuda, T.3
-
10
-
-
33748154637
-
HER-2/neu amplification is an independent prognostic factor in gastric cancer
-
DOI 10.1007/s10620-005-9057-1
-
Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379 (Pubitemid 44315804)
-
(2006)
Digestive Diseases and Sciences
, vol.51
, Issue.8
, pp. 1371-1379
-
-
Park, D.I.1
Yun, J.W.2
Park, J.H.3
Oh, S.J.4
Kim, H.J.5
Cho, Y.K.6
Sohn, C.I.7
Jeon, W.K.8
Kim, B.I.9
Yoo, C.H.10
Son, B.H.11
Cho, E.Y.12
Chae, S.W.13
Kim, E.-J.14
Sohn, J.H.15
Ryu, S.H.16
Sepulveda, A.R.17
-
11
-
-
0025974889
-
Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer
-
Yonemura Y, Ninomiya I, Yamaguchi A et al (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 51:1034-1038
-
(1991)
Cancer Res
, vol.51
, pp. 1034-1038
-
-
Yonemura, Y.1
Ninomiya, I.2
Yamaguchi, A.3
-
12
-
-
20044372721
-
Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
-
DOI 10.1093/annonc/mdi064
-
Tanner M, Hollmen M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278 (Pubitemid 40309309)
-
(2005)
Annals of Oncology
, vol.16
, Issue.2
, pp. 273-278
-
-
Tanner, M.1
Hollmen, M.2
Junttila, T.T.3
Kapanen, A.I.4
Tommola, S.5
Soini, Y.6
Helin, H.7
Salo, J.8
Joensuu, H.9
Sihvo, E.10
Elenius, K.11
Isola, J.12
-
13
-
-
50849123421
-
HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target
-
Grávalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
-
(2008)
Ann Oncol
, vol.19
, pp. 1523-1529
-
-
Grávalos, C.1
Jimeno, A.2
-
14
-
-
24344489058
-
Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model
-
Matsui Y, Inomata M, Tojigamori M et al (2005) Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 27:681-685
-
(2005)
Int J Oncol
, vol.27
, pp. 681-685
-
-
Matsui, Y.1
Inomata, M.2
Tojigamori, M.3
-
15
-
-
33947320114
-
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models
-
DOI 10.1007/s00280-006-0337-z
-
Fujimoto-Ouchi K, Sekiguchi F, Yasuno H et al (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59:795-805 (Pubitemid 46440603)
-
(2007)
Cancer Chemotherapy and Pharmacology
, vol.59
, Issue.6
, pp. 795-805
-
-
Fujimoto-Ouchi, K.1
Sekiguchi, F.2
Yasuno, H.3
Moriya, Y.4
Mori, K.5
Tanaka, Y.6
-
16
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
-
(1989)
Control Clin Trials
, vol.10
, pp. 1-10
-
-
Simon, R.1
-
17
-
-
33644833992
-
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
-
DOI 10.1200/JCO.2005.04.2994
-
Ajani JA, Lee FC, Singh DA et al (2006) Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:663-667 (Pubitemid 46630431)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.4
, pp. 663-667
-
-
Ajani, J.A.1
Lee, F.-C.2
Singh, D.A.3
Haller, D.G.4
Lenz, H.-J.5
Benson III, A.B.6
Yanagihara, R.7
Phan, A.T.8
Yao, J.C.9
Strumberg, D.10
-
18
-
-
0035131823
-
Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer
-
DOI 10.1023/A:1008328501128
-
Ridwelski K, Gebauer T, Fahlke J et al (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47-51 (Pubitemid 32162447)
-
(2001)
Annals of Oncology
, vol.12
, Issue.1
, pp. 47-51
-
-
Ridwelski, K.1
Gebauer, T.2
Fahlke, J.3
Kroning, H.4
Kettner, E.5
Meyer, F.6
Eichelmann, K.7
Lippert, H.8
-
19
-
-
0034154069
-
Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma
-
DOI 10.1023/A:1008342013224
-
Roth AD, Maibach R, Martinelli G et al (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Res (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301-306 (Pubitemid 30214667)
-
(2000)
Annals of Oncology
, vol.11
, Issue.3
, pp. 301-306
-
-
Roth, A.D.1
Maibach, R.2
Martinelli, G.3
Fazio, N.4
Aapro, M.S.5
Pagani, O.6
Morant, R.7
Borner, M.M.8
Herrmann, R.9
Honegger, H.10
Cavalli, F.11
Alberto, P.12
Castiglione, M.13
Goldhirsch, A.14
-
20
-
-
24944465318
-
A multi-institutional phase II randomized trial of docetaxel plus cisplatin (DC) or DC plus 5-fluorouracil (DCF) in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
-
Ajani JA, Fodor MB, Tjulandin SA et al (2005) A multi-institutional phase II randomized trial of docetaxel plus cisplatin (DC) or DC plus 5-fluorouracil (DCF) in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660-5667
-
(2005)
J Clin Oncol
, vol.23
, pp. 5660-5667
-
-
Ajani, J.A.1
Fodor, M.B.2
Tjulandin, S.A.3
-
21
-
-
33750949065
-
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V25 study group
-
DOI 10.1200/JCO.2006.06.8429
-
Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991-4997 (Pubitemid 46631401)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.31
, pp. 4991-4997
-
-
Van Cutsem, E.1
Moiseyenko, V.M.2
Tjulandin, S.3
Majlis, A.4
Constenla, M.5
Boni, C.6
Rodrigues, A.7
Fodor, M.8
Chao, Y.9
Voznyi, E.10
Risse, M.-L.11
Ajani, J.A.12
-
22
-
-
0034082031
-
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
-
Colomer R, Montero S, Lluch A et al (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6:2356-2362 (Pubitemid 30399203)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.6
, pp. 2356-2362
-
-
Colomer, R.1
Montero, S.2
Lluch, A.3
Ojeda, B.4
Barnadas, A.5
Casado, A.6
Massuti, B.7
Cortes-Funes, H.8
Lloveras, B.9
-
23
-
-
14644401104
-
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
-
DOI 10.1093/annonc/mdi059
-
Fornier MN, Seidman AD, Schwartz MK et al (2006) Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16:234-239 (Pubitemid 40309302)
-
(2005)
Annals of Oncology
, vol.16
, Issue.2
, pp. 234-239
-
-
Fornier, M.N.1
Seidman, A.D.2
Schwartz, M.K.3
Ghani, F.4
Thiel, R.5
Norton, L.6
Hudis, C.7
-
24
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
-
Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697
-
(2010)
Lancet
, vol.376
, Issue.9742
, pp. 687-697
-
-
Bang, Y.J.1
Van Cutsem, E.2
Feyereislova, A.3
-
25
-
-
67650395446
-
Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2
-
abstr 1105
-
Nicholas G, Cripps C, Au H-P et al (2006) Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2. ESMO abstr 1105
-
(2006)
ESMO
-
-
Nicholas, G.1
Cripps, C.2
Au, H.-P.3
-
26
-
-
50849143901
-
A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer
-
abstr 1096
-
Rech J, Arnold D, Folprecht G et al (2006) A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. ESMO abstr 1096
-
(2006)
ESMO
-
-
Rech, J.1
Arnold, D.2
Folprecht, G.3
|